Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Galeas Soriano

Hematology & Oncology Mobile, AL Medical Doctor

NPI 1003255993 CMS profile 6956448

1700 Spring Hill Ave Ste 100, Mobile, AL 36604

Open in the dashboard

General payments

$16,736

465 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$519,479 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Jose Galeas Soriano of Mobile, AL is reported in the CMS Open Payments database as having received $16,736 across 465 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $519,479 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 78th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,969 7
2024 General $4,348 94
2023 General $4,050 150
2022 General $2,448 135
2021 General $829 39
2020 General $524 21
2019 General $569 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Galeas Soriano
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Jose Galeas Soriano were reported at $3,969. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Jose Galeas Soriano Hematology & Oncology median Middle half National median
2019 $569 $529 $121–$2,516 $163
2020 $524 $339 $82–$2,213 $114
2021 $829 $263 $49–$1,965 $132
2022 $2,448 $416 $103–$2,395 $149
2023 $4,050 $542 $125–$2,646 $160
2024 $4,348 $692 $141–$3,008 $164
2025 $3,969 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $5,914 44 payments
  2. Merck Sharp & Dohme Corporation $1,449 28 payments
  3. Gilead Sciences, Inc. $1,246 6 payments
  4. Novartis Pharmaceuticals Corporation $947 48 payments
  5. Amgen Inc. $541 28 payments
  6. Celgene Corporation $484 24 payments
  7. Eisai Inc. $438 21 payments
  8. Janssen Biotech, Inc. $437 26 payments
  9. Pfizer Inc. $429 25 payments
  10. Genzyme Corporation $403 13 payments
  11. Other $4,449 202 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,698 450 payments
  2. Consulting Fee $6,200 4 payments
  3. Travel and Lodging $725 3 payments
  4. Education $113 8 payments
Products named General payments · program years 2019–2025
  1. TAGRISSO $2,472 2 payments
  2. KEYTRUDA $1,432 27 payments
  3. Trodelvy $1,216 4 payments
  4. CALQUENCE $829 12 payments
  5. Lenvima $438 21 payments
  6. KISQALI $406 19 payments
  7. LIBTAYO $354 15 payments
  8. OPDIVO $285 15 payments
  9. DARZALEX $284 12 payments
  10. ERLEADA $265 10 payments
  11. Other $8,552 432 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,395

Median for Medical Oncology: 414

Drug cost

$1,500,943

Median for Medical Oncology: $849,427

Branded share of claims

32.3%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Verzenio Abemaciclib Brand 33 $473,945
Tagrisso Osimertinib Mesylate Brand 32 $338,517
Revlimid Lenalidomide Brand 12 $229,113
Ibrance Palbociclib Brand 11 $203,490
Kisqali Ribociclib Succinate Brand 15 $192,028
Eliquis Apixaban Brand 46 $33,523
Veozah Fezolinetant Brand 11 $6,065
Anastrozole Generic 196 $4,155
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 92 $3,303
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 90 $2,442

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 193 billing codes

Paid by Medicare

$416,268

Of which drugs: $258,126

Medicare patients

629

Average age 74

Services billed

31,597

372 women, 257 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 44%
Cancer 44%
Diabetes 39%
Chronic kidney disease 39%
COPD 27%
Heart failure 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 23 424 $37
Infusion, normal saline solution , 1000 cc J7030 Office 12 17 $34
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 11 22 $22
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 13 29 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 52 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CALQUENCE
  • AstraZeneca Pharmaceuticals LP $560
$560 — —
KISQALI
  • Novartis Pharmaceuticals Corporation $137
$137 15 —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $102
$102 — —
ENHERTU
  • Daiichi Sankyo Inc. $84
  • AstraZeneca Pharmaceuticals LP $14
$98 — —
REBLOZYL
  • Celgene Corporation $66
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 52 with Patron

Records

465 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record